Baseline patient characteristics
| Number of patients with prosthetic joints | nbDMARD (n=659) | Anti-TNF (n=2689) |
|---|---|---|
| Exposure time (years)* | 1954 | 12 959 |
| Events | 6 | 41 |
| Incidence prosthetic joint SA/1000 pyrs (95% CI) | 3.1 (1.1 to 6.7) | 3.2 (2.3 to 4.3) |
| Adjusted HR (95% CI) | Ref | 1.2 (0.4 to 3.4) |
↵* Patients were included in this analysis only if they had a prosthetic joint in situ.
Anti-TNF, anti-tumour necrosis factor; nbDMARD, non-biological disease-modifying antirheumatic drug; pyrs, patient years.